Universität zu Köln

2018

Schuler, M., Cassier, P., Penel, N., Cathomas, R., Richly, H., Schostak, M., Janitzky, A., Wermke, M., Nogova, L., Tai, D., Sayehli, C., Gruellich, C., Grande, E., Navarro, A., Park, S. H., Nogai, H., Bender, S., Ellinghaus, P. and Joerger, M. (2018). Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway. Oncol. Res. Treat., 41. S. 321 - 322. BASEL: KARGER. ISSN 2296-5262

2017

Schuler, M., Nogova, L., Heidenreich, A., Tai, D., Cassier, P., Richly, H., Cho, B. C., Sayehli, C. M., Navarro, A., Bender, S., Ocker, M., Nogai, H., Wagner, A., Ince, S., Ellinghaus, P. and Joerger, M. (2017). Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

2016

Joerger, M., Soo, R., Cho, B. C., Navarro Mendivil, A., Sayehli, C., Richly, H., Tai, D., Kim, D. -W., Wolf, J., Cassier, P., Ellinghaus, P., Hildebrandt, S., Behre, S., Helmbrecht, C., Kerpen, S., Zielinski, D., Ince, S., Rajagopalan, P., Ocker, M. and Schuler, M. (2016). Phase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

2010

Weihrauch, M. R., Richly, H., von Bergwelt-Baildon, M. S., Hacker, U., Shimabukuro-Vornhagen, A., Nokay, B., Tschaika, M., Schmidt, M., Wittig, B. and Scheulen, M. E. (2010). Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - safety results of a clinical phase I study. EJC Suppl., 8 (7). S. 24 - 25. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1359-6349

Weihrauch, M. R., von Bergwelt-Baildon, M. S., Hacker, U., Richly, H., Holtick, U., Tschaika, M., Schmidt, M., Wittig, B., Nokay, B. and Scheulen, M. E. (2010). Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - clinical efficacy and immunological results of a phase I study. EJC Suppl., 8 (7). S. 23 - 25. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1359-6349